Appraisal of candidate instruments for assessment of the physical function domain in patients with psoriatic arthritis

Ying Ying Leung; Ana Maria Orbai; Alexis Ogdie; Pil Hojgaard; Richard Holland; Niti Goel; Jeffrey Chau; Laura C. Coates; Vibeke Strand; Dafna D. Gladman; Philip J. Mease; Robin Christensen; William Tillett

doi:10.3899/JRHEUM.191119

Appraisal of candidate instruments for assessment of the physical function domain in patients with psoriatic arthritis

Ying Ying Leung, Ana Maria Orbai, Alexis Ogdie, Pil Hojgaard, Richard Holland, Niti Goel, Jeffrey Chau, Laura C. Coates, Vibeke Strand, Dafna D. Gladman, Philip J. Mease, Robin Christensen, William Tillett

Research output: Contribution to journal › Article › peer-review

5 Citations (SciVal)

53 Downloads (Pure)

Abstract

Objective. Numerous patient-reported outcome measures (PROM) exist for the measurement of physical function for psoriatic arthritis (PsA), but only a few are validated comprehensively. The objective of this project was to prioritize PROM for measuring physical function for potential incorporation into a standardized outcome measurement set for PsA. Methods. A working group of 13 members including 2 patient research partners was formed. PROM measuring physical function in PsA were identified through a systematic literature review and recommendations by the working group. The rationale for inclusion and exclusion from the original list of existing PROM was thoroughly discussed and 2 rounds of Delphi exercises were conducted to achieve consensus. Results. Twelve PROM were reviewed and discussed. Six PROM were prioritized: Health Assessment Questionnaire (HAQ) and 4 modifications (HAQ-Disability Index, HAQ-Spondyloarthritis, modified HAQ, multidimensional HAQ), Medical Outcomes Study 36-item Short Form survey physical functioning domain, and the Patient-Reported Outcomes Measurement Information System (PROMIS) physical functioning module. Conclusion. Through discussion and Delphi exercises, we achieved consensus to prioritize 6 physical function PROM for PsA. These 6 PROM will undergo further appraisal using the Outcome Measures in Rheumatology (OMERACT) Filter 2.1.

Original language	English
Pages (from-to)	58-66
Number of pages	9
Journal	Journal of Rheumatology
Volume	48
Issue number	1
Early online date	1 Jan 2021
DOIs	https://doi.org/10.3899/JRHEUM.191119
Publication status	Published - 1 Jan 2021

Bibliographical note

Funding Information:
YYL is funded by the Clinician Scientist award of the National Medical Research Council, Singapore (NMRC/CSA-INV/0022/2017). The views expressed are those of the author(s) and not necessarily those of the NMRC. AMO is funded by the Jerome L. Greene Foundation Scholar Award, the Staurulakis Family Discovery Award, the Rheumatology Research Foundation, and the US National Institutes of Health (NIH) through the Rheumatic Diseases Resource-based Core Center (P30-AR053503 Cores A and D, and P30-AR070254, Cores A and B). All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the NIH, the US National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS), or the Rheumatology Research Foundation. PH and RC (The Parker Institute, Bispebjerg and Frederiksberg Hospital) are supported by a core grant from the Oak Foundation (OCAY-18-774-OFIL). LCC is funded by a UK National Institute for Health Research (NIHR) Clinician Scientist award. The research was supported by the NIHR Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the UK National Health Service, the NIHR, or the UK Department of Health. AO is funded by the Rheumatology Research Foundation and NIH/NIAMS R01 AR072363. 1Y.Y. Leung, MB ChB, MD, Associate Professor, Duke-NUS Medical School, Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; 2A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Director Psoriatic Arthritis Program, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; 3A. Ogdie, MD, MSCE, Associate Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; 4P. Hojgaard, MD, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; 5R. Holland, MBBS, Concord Repatriation General Hospital, Sydney, Australia; 6N. Goel, MD, Patient Research Partner, Adjunct Assistant Professor, Duke University School of Medicine, Durham, North Carolina, USA; 7J. Chau, BBA, Patient Research Partner, Hong Kong Psoriatic Arthritis Association, Hong Kong, China; 8L.C. Coates, MB ChB, PhD, National Institute for Health Research Clinician Scientist, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; 9V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; 10D.D. Gladman, MD, FRCPC, Division of Rheumatology, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada; 11P.J. Mease, MD, Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington, USA; 12R. Christensen, BSc, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, and Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Denmark; 13W. Tillett, BSc, MB ChB, PhD, MRCP, Consultant Rheumatologist, Senior Lecturer, Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK. Address correspondence to Dr. Y.Y. Leung, Department of Rheumatology and Immunology, Singapore General Hospital, The Academia, Level 4, 20 College Road, Singapore 169856. Email: [email protected]. Accepted for publication January 17, 2020.

Publisher Copyright:
© 2021 Journal of Rheumatology. All rights reserved.

Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.

Keywords

Outcome measures
Physical function
Psoriasis
Psoriatic arthritis

ASJC Scopus subject areas

Rheumatology
Immunology and Allergy
Immunology

Access to Document

10.3899/JRHEUM.191119

PSA_Physical_functioning_instrument_prioritization_article_version_for_submission.PDF
This is the author accepted manuscript of an article published in final form in Leung, YY, Orbai, AM, Ogdie, A, Hojgaard, P, Holland, R, Goel, N, Chau, J, Coates, LC, Strand, V, Gladman, DD, Mease, PJ, Christensen, R & Tillett, W 2021, 'Appraisal of candidate instruments for assessment of the physical function domain in patients with psoriatic arthritis', Journal of Rheumatology, vol. 48, no. 1, pp. 58-66 and available online via: https://doi.org/10.3899/jrheum.191119
Accepted author manuscript, 625 KB

Cite this

Leung, Y. Y., Orbai, A. M., Ogdie, A., Hojgaard, P., Holland, R., Goel, N., Chau, J., Coates, L. C., Strand, V., Gladman, D. D., Mease, P. J., Christensen, R., & Tillett, W. (2021). Appraisal of candidate instruments for assessment of the physical function domain in patients with psoriatic arthritis. Journal of Rheumatology, 48(1), 58-66. https://doi.org/10.3899/JRHEUM.191119

@article{eb831b17c7d741b8a862bbd1a2925c2d,

title = "Appraisal of candidate instruments for assessment of the physical function domain in patients with psoriatic arthritis",

abstract = "Objective. Numerous patient-reported outcome measures (PROM) exist for the measurement of physical function for psoriatic arthritis (PsA), but only a few are validated comprehensively. The objective of this project was to prioritize PROM for measuring physical function for potential incorporation into a standardized outcome measurement set for PsA. Methods. A working group of 13 members including 2 patient research partners was formed. PROM measuring physical function in PsA were identified through a systematic literature review and recommendations by the working group. The rationale for inclusion and exclusion from the original list of existing PROM was thoroughly discussed and 2 rounds of Delphi exercises were conducted to achieve consensus. Results. Twelve PROM were reviewed and discussed. Six PROM were prioritized: Health Assessment Questionnaire (HAQ) and 4 modifications (HAQ-Disability Index, HAQ-Spondyloarthritis, modified HAQ, multidimensional HAQ), Medical Outcomes Study 36-item Short Form survey physical functioning domain, and the Patient-Reported Outcomes Measurement Information System (PROMIS) physical functioning module. Conclusion. Through discussion and Delphi exercises, we achieved consensus to prioritize 6 physical function PROM for PsA. These 6 PROM will undergo further appraisal using the Outcome Measures in Rheumatology (OMERACT) Filter 2.1.",

keywords = "Outcome measures, Physical function, Psoriasis, Psoriatic arthritis",

author = "Leung, {Ying Ying} and Orbai, {Ana Maria} and Alexis Ogdie and Pil Hojgaard and Richard Holland and Niti Goel and Jeffrey Chau and Coates, {Laura C.} and Vibeke Strand and Gladman, {Dafna D.} and Mease, {Philip J.} and Robin Christensen and William Tillett",

note = "Funding Information: YYL is funded by the Clinician Scientist award of the National Medical Research Council, Singapore (NMRC/CSA-INV/0022/2017). The views expressed are those of the author(s) and not necessarily those of the NMRC. AMO is funded by the Jerome L. Greene Foundation Scholar Award, the Staurulakis Family Discovery Award, the Rheumatology Research Foundation, and the US National Institutes of Health (NIH) through the Rheumatic Diseases Resource-based Core Center (P30-AR053503 Cores A and D, and P30-AR070254, Cores A and B). All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the NIH, the US National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS), or the Rheumatology Research Foundation. PH and RC (The Parker Institute, Bispebjerg and Frederiksberg Hospital) are supported by a core grant from the Oak Foundation (OCAY-18-774-OFIL). LCC is funded by a UK National Institute for Health Research (NIHR) Clinician Scientist award. The research was supported by the NIHR Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the UK National Health Service, the NIHR, or the UK Department of Health. AO is funded by the Rheumatology Research Foundation and NIH/NIAMS R01 AR072363. 1Y.Y. Leung, MB ChB, MD, Associate Professor, Duke-NUS Medical School, Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; 2A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Director Psoriatic Arthritis Program, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; 3A. Ogdie, MD, MSCE, Associate Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; 4P. Hojgaard, MD, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; 5R. Holland, MBBS, Concord Repatriation General Hospital, Sydney, Australia; 6N. Goel, MD, Patient Research Partner, Adjunct Assistant Professor, Duke University School of Medicine, Durham, North Carolina, USA; 7J. Chau, BBA, Patient Research Partner, Hong Kong Psoriatic Arthritis Association, Hong Kong, China; 8L.C. Coates, MB ChB, PhD, National Institute for Health Research Clinician Scientist, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; 9V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; 10D.D. Gladman, MD, FRCPC, Division of Rheumatology, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada; 11P.J. Mease, MD, Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington, USA; 12R. Christensen, BSc, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, and Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Denmark; 13W. Tillett, BSc, MB ChB, PhD, MRCP, Consultant Rheumatologist, Senior Lecturer, Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK. Address correspondence to Dr. Y.Y. Leung, Department of Rheumatology and Immunology, Singapore General Hospital, The Academia, Level 4, 20 College Road, Singapore 169856. Email: [email protected]. Accepted for publication January 17, 2020. Publisher Copyright: {\textcopyright} 2021 Journal of Rheumatology. All rights reserved. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2021",

month = jan,

day = "1",

doi = "10.3899/JRHEUM.191119",

language = "English",

volume = "48",

pages = "58--66",

journal = "Journal of Rheumatology",

issn = "0315-162X",

publisher = "Journal of Rheumatology",

number = "1",

}

TY - JOUR

T1 - Appraisal of candidate instruments for assessment of the physical function domain in patients with psoriatic arthritis

AU - Leung, Ying Ying

AU - Orbai, Ana Maria

AU - Ogdie, Alexis

AU - Hojgaard, Pil

AU - Holland, Richard

AU - Goel, Niti

AU - Chau, Jeffrey

AU - Coates, Laura C.

AU - Strand, Vibeke

AU - Gladman, Dafna D.

AU - Mease, Philip J.

AU - Christensen, Robin

AU - Tillett, William

N1 - Funding Information: YYL is funded by the Clinician Scientist award of the National Medical Research Council, Singapore (NMRC/CSA-INV/0022/2017). The views expressed are those of the author(s) and not necessarily those of the NMRC. AMO is funded by the Jerome L. Greene Foundation Scholar Award, the Staurulakis Family Discovery Award, the Rheumatology Research Foundation, and the US National Institutes of Health (NIH) through the Rheumatic Diseases Resource-based Core Center (P30-AR053503 Cores A and D, and P30-AR070254, Cores A and B). All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the NIH, the US National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS), or the Rheumatology Research Foundation. PH and RC (The Parker Institute, Bispebjerg and Frederiksberg Hospital) are supported by a core grant from the Oak Foundation (OCAY-18-774-OFIL). LCC is funded by a UK National Institute for Health Research (NIHR) Clinician Scientist award. The research was supported by the NIHR Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the UK National Health Service, the NIHR, or the UK Department of Health. AO is funded by the Rheumatology Research Foundation and NIH/NIAMS R01 AR072363. 1Y.Y. Leung, MB ChB, MD, Associate Professor, Duke-NUS Medical School, Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; 2A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Director Psoriatic Arthritis Program, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; 3A. Ogdie, MD, MSCE, Associate Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; 4P. Hojgaard, MD, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; 5R. Holland, MBBS, Concord Repatriation General Hospital, Sydney, Australia; 6N. Goel, MD, Patient Research Partner, Adjunct Assistant Professor, Duke University School of Medicine, Durham, North Carolina, USA; 7J. Chau, BBA, Patient Research Partner, Hong Kong Psoriatic Arthritis Association, Hong Kong, China; 8L.C. Coates, MB ChB, PhD, National Institute for Health Research Clinician Scientist, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; 9V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; 10D.D. Gladman, MD, FRCPC, Division of Rheumatology, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada; 11P.J. Mease, MD, Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington, USA; 12R. Christensen, BSc, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, and Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Denmark; 13W. Tillett, BSc, MB ChB, PhD, MRCP, Consultant Rheumatologist, Senior Lecturer, Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK. Address correspondence to Dr. Y.Y. Leung, Department of Rheumatology and Immunology, Singapore General Hospital, The Academia, Level 4, 20 College Road, Singapore 169856. Email: [email protected]. Accepted for publication January 17, 2020. Publisher Copyright: © 2021 Journal of Rheumatology. All rights reserved. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/1/1

Y1 - 2021/1/1

N2 - Objective. Numerous patient-reported outcome measures (PROM) exist for the measurement of physical function for psoriatic arthritis (PsA), but only a few are validated comprehensively. The objective of this project was to prioritize PROM for measuring physical function for potential incorporation into a standardized outcome measurement set for PsA. Methods. A working group of 13 members including 2 patient research partners was formed. PROM measuring physical function in PsA were identified through a systematic literature review and recommendations by the working group. The rationale for inclusion and exclusion from the original list of existing PROM was thoroughly discussed and 2 rounds of Delphi exercises were conducted to achieve consensus. Results. Twelve PROM were reviewed and discussed. Six PROM were prioritized: Health Assessment Questionnaire (HAQ) and 4 modifications (HAQ-Disability Index, HAQ-Spondyloarthritis, modified HAQ, multidimensional HAQ), Medical Outcomes Study 36-item Short Form survey physical functioning domain, and the Patient-Reported Outcomes Measurement Information System (PROMIS) physical functioning module. Conclusion. Through discussion and Delphi exercises, we achieved consensus to prioritize 6 physical function PROM for PsA. These 6 PROM will undergo further appraisal using the Outcome Measures in Rheumatology (OMERACT) Filter 2.1.

AB - Objective. Numerous patient-reported outcome measures (PROM) exist for the measurement of physical function for psoriatic arthritis (PsA), but only a few are validated comprehensively. The objective of this project was to prioritize PROM for measuring physical function for potential incorporation into a standardized outcome measurement set for PsA. Methods. A working group of 13 members including 2 patient research partners was formed. PROM measuring physical function in PsA were identified through a systematic literature review and recommendations by the working group. The rationale for inclusion and exclusion from the original list of existing PROM was thoroughly discussed and 2 rounds of Delphi exercises were conducted to achieve consensus. Results. Twelve PROM were reviewed and discussed. Six PROM were prioritized: Health Assessment Questionnaire (HAQ) and 4 modifications (HAQ-Disability Index, HAQ-Spondyloarthritis, modified HAQ, multidimensional HAQ), Medical Outcomes Study 36-item Short Form survey physical functioning domain, and the Patient-Reported Outcomes Measurement Information System (PROMIS) physical functioning module. Conclusion. Through discussion and Delphi exercises, we achieved consensus to prioritize 6 physical function PROM for PsA. These 6 PROM will undergo further appraisal using the Outcome Measures in Rheumatology (OMERACT) Filter 2.1.

KW - Outcome measures

KW - Physical function

KW - Psoriasis

KW - Psoriatic arthritis

UR - http://www.scopus.com/inward/record.url?scp=85090404192&partnerID=8YFLogxK

U2 - 10.3899/JRHEUM.191119

DO - 10.3899/JRHEUM.191119

M3 - Article

C2 - 32007934

AN - SCOPUS:85090404192

SN - 0315-162X

VL - 48

SP - 58

EP - 66

JO - Journal of Rheumatology

JF - Journal of Rheumatology

IS - 1

ER -

Appraisal of candidate instruments for assessment of the physical function domain in patients with psoriatic arthritis

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Outcome Measures for Randomised Controlled Trials in Psoriatic Arthritis

Cite this

Appraisal of candidate instruments for assessment of the physical function domain in patients with psoriatic arthritis

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Projects

Outcome Measures for Randomised Controlled Trials in Psoriatic Arthritis

Cite this